




# NEED ADHD TREATMENT RESOURCES?

**Qelbree**<sup>®</sup> **ONCE-DAILY**   
viloxazine  
extended-release capsules  
100 mg 150 mg 200 mg

## INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

## IMPORTANT SAFETY INFORMATION

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

Please see full [Important Safety Information](#) on page 3 and full [Prescribing Information](#), including Boxed Warning.

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.



The **Qelbree Co-pay Card** helps patients access the care they need.



Commercially insured patients may pay as little as \$20 per prescription for a 30-day or 90-day prescription!\*

\*Terms and conditions apply.

Access to the **Qelbree Co-pay Card** is available in a variety of ways:



In-office brochures



Downloadable at **Qelbree.com**



Downloadable on **GoodRx**

Card not working? Call  
**1-855-725-7736.**

Please see full [Important Safety Information](#) on page 3 and full [Prescribing Information](#), including **Boxed Warning**.



**Qelbree** is available in pharmacies nationwide.



**Qelbree** is available or listed on

**covermymeds®**

[covermymeds.com](https://covermymeds.com).



Order **Qelbree** samples online:



Scan here or go to

**Qelbree HCP.com.**



**Have questions? We have answers!**

**Supernus®  
Support**

**1-866-398-0833**

Open Monday to Friday from  
8:30 am to 6:30 pm ET.

## INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

## IMPORTANT SAFETY INFORMATION

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

**In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.**

## CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

## WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy

## WARNINGS & PRECAUTIONS (CONT'D)

- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree


## ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

## PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting [www.womensmentalhealth.org/preg](http://www.womensmentalhealth.org/preg).

Please see full [Prescribing Information](#), including Boxed Warning.

**Qelbree** <sup>ONCE-DAILY</sup>   
viloxazine  
extended-release capsules  
100 mg 150 mg 200 mg



# NEED ADHD TREATMENT RESOURCES?



## INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

## IMPORTANT SAFETY INFORMATION

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

**In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.**

Please see full [Important Safety Information](#) on page 3 and full [Prescribing Information](#), including Boxed Warning.



Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.  
©2026 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2026-0037